TrialCancer immunology, immunotherapy : CII2026

Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study.

Qianyi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.